Our collaboration strategy is a key element to executing our vision of rewriting oncology treatment with epigenetics. We strive to be a partner of choice as we enter strategic partnerships and collaborations that contribute to our ability to advance our therapeutic product candidates, build our product platform and concurrently progress a wide range of discovery and development programs.
If you or your company are interested in collaboration and partnering opportunities, contact us at BD@epizyme.com.
Epizyme has entered into several strategic collaborations:
|In August 2021, we entered into a collaboration to research, develop, manufacture and commercialize TAZVERIK® (tazemetostat) in Greater China with HUTCHMED. This collaboration is designed to accelerate global development and investigate TAZVERIK® combinations with HUTCHMED’s novel oncology medicines portfolio. Under the terms of the agreement, HUTCHMED will be responsible for the development and commercialization of TAZVERIK® in Greater China.||In June 2021, we launched the EZH2NowSM Testing Program, in collaboration with Quest Diagnostics, to provide nationally available single gene EZH2 testing for patients with relapsed or refractory (R/R) follicular lymphoma (FL). While EZH2 dependence can be present regardless of mutation status, single gene testing may provide helpful information for physicians to better characterize their patients’ cancer.|
|In May 2016, we entered into a research collaboration agreement with the Lymphoma Study Association (LYSA) to investigate the combination of tazemetostat with R-CHOP, a standard chemotherapy for non-Hodgkin’s lymphoma (NHL), as a front-line treatment in elderly, high-risk patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). In 2020, we expanded the collaboration to include Follicular Lymphoma. The Lymphoma Academic Research Organisation (LYSARC), the operational arm of LYSA, is currently conducting a clinical Phase 1b/2 study to evaluate tazemetostat with R-CHOP in both elderly, high risk patients with newly diagnosed DLBCL as well as elderly, high risk patients with newly diagnosed follicular lymphoma (FL) across multiple sites in France.||After an initial out-license agreement in 2011, in March 2015, we reacquired worldwide rights excluding Japan to tazemetostat following an amended and restated collaboration and license agreement. We are responsible for global development and commercialization outside of Japan of tazemetostat and any other EZH2 product candidates, with Eisai retaining development and commercialization rights in Japan.|
|In December 2012 we entered into an agreement with Roche Molecular Systems, Inc., to develop and commercialize a companion diagnostic to identify cancer patients who have certain EZH2 mutations. We used the diagnostic test designed in collaboration with Roche to identify EZH2 mutations in patients that participated in our multi-arm Phase 2 study in NHL that led to the FDA approval of tazemetostat in relapsed or refractory Follicular Lymphoma in 2020.||In January 2011, we entered into a collaboration and license agreement with GlaxoSmithKline (GSK) to discover, develop and commercialize novel small molecule histone methyltransferase (HMT) inhibitors directed to three targets from our product platform. We discovered 3 programs under the research collaboration and GSK elected to enter 2 programs into clinical development. Under the agreement, GSK is solely responsible for the development and commercialization of the programs and we are eligible to receive certain development and regulatory milestone payments as well as royalties on worldwide net product sales.|